Bryan M. Reasons's Insider Trades & SAST Disclosures
Bryan M. Reasons's most recent trade in Aclaris Therapeutics Inc was a trade of 4,660 Restricted Stock Units done . Disclosure was reported to the exchange on June 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bryan M. Reasons.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 28,732 (0%) | 0% | - | Common Stock | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Purchase of securities on an exchange or from another person at price $ 0.40 per share. | 28 Aug 2023 | 62,500 | 291,049 (1%) | 0% | 0.4 | 25,000 | Common Stock |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 24,072 (0%) | 0% | - | Common Stock | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 73,620 | 228,549 (0%) | 0% | - | Common Stock | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 27,229 | 27,229 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 19,565 (0%) | 0% | - | Common Stock | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 118,182 | 118,182 | - | - | Stock Option (right to buy) | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 87,500 | 154,929 (0%) | 0% | - | Common Stock | |
| Societal CDMO Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2021 | 38,012 | 38,012 | - | - | Stock Option (right to buy) | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 16,500 | 16,500 | - | - | Option Grant (right to buy) | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 7,333 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Bryan M. Reasons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 7,333 | 16,209 (0%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges